Cordiano I, Betterle C, Spadaccino C A, Soini B, Girolami A, Fabris F
Institute of Medical Semeiotic, University of Padua Medical School, Padova, Italy.
Clin Exp Immunol. 1998 Sep;113(3):373-8. doi: 10.1046/j.1365-2249.1998.00677.x.
The pathogenesis of thrombocytopenia associated with TAD and the occurrence of overlapping traits between TAD and AITP are still a matter of debate. For this reason, we investigated for the presence and specificity of platelet and thyroid autoantibodies in 18 TAD patients with thrombocytopenia, 19 TAD patients without thrombocytopenia and in 22 patients with primary AITP without clinical signs of TAD. Platelet-associated IgG and/or specific circulating platelet autoantibodies were detected in 83% of patients with TAD and thrombocytopenia, in 10% of patients with TAD without thrombocytopenia and in 86% of patients with primary AITP. The reactivity of serum autoantibodies, assayed by MoAb immobilization of platelet antigens (MAIPA), was directed against platelet glycoproteins Ib and/or IIb/IIIa in 50% of the patients with TAD and thrombocytopenia, as in 46% of the patients with primary AITP. Thyroid autoantibodies were found in 89% of patients with TAD and thrombocytopenia, in 95% of patients with TAD without thrombocytopenia, and in 18% of patients with primary AITP. Thyrotropin (TSH) levels determined in three of four AITP patients with thyroid autoantibodies revealed a subclinical hyperthyroidism in one patient. The present study supports the autoimmune aetiology of thrombocytopenia associated with TAD, since the prevalence and specificity of platelet autoantibodies are similar in TAD and primary AITP. The results indicate also that there exists an overlap between thyroid and platelet autoimmunity with or without clinical manifestations.
与自身免疫性甲状腺疾病(TAD)相关的血小板减少症的发病机制以及TAD与自身免疫性血小板减少性紫癜(AITP)之间重叠特征的出现仍存在争议。因此,我们调查了18例伴有血小板减少症的TAD患者、19例无血小板减少症的TAD患者以及22例无TAD临床症状的原发性AITP患者中血小板和甲状腺自身抗体的存在情况及特异性。在伴有血小板减少症的TAD患者中,83%检测到血小板相关IgG和/或特异性循环血小板自身抗体;在无血小板减少症的TAD患者中,这一比例为10%;在原发性AITP患者中,这一比例为86%。通过单克隆抗体固定血小板抗原法(MAIPA)检测血清自身抗体的反应性,在50%伴有血小板减少症的TAD患者中,血清自身抗体针对血小板糖蛋白Ib和/或IIb/IIIa,原发性AITP患者中的这一比例为46%。在伴有血小板减少症的TAD患者中,89%检测到甲状腺自身抗体;在无血小板减少症的TAD患者中,这一比例为95%;在原发性AITP患者中,这一比例为18%。在4例伴有甲状腺自身抗体的AITP患者中,对其中3例测定促甲状腺激素(TSH)水平,发现1例患者存在亚临床甲状腺功能亢进。本研究支持与TAD相关的血小板减少症的自身免疫病因,因为TAD和原发性AITP中血小板自身抗体的患病率和特异性相似。结果还表明,无论有无临床表现,甲状腺和血小板自身免疫之间都存在重叠。